1. Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010;29:213-40. PMID:
20025020
2. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36. PMID:
12811491
3. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2011;77:1081-7. PMID:
21256571
4. Chapple C. Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of “overactive bladder”. Neurourol Urodyn 2014;33 Suppl 3:S6-13. PMID:
25042142
5. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-61. PMID:
12606176
6. den Boer JA, Westenberg HG, De Leeuw AS, van Vliet IM. Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. Int Clin Psychopharmacol 1995;9 Suppl 4:47-52. PMID:
7622824
8. Kyle CJ, Petersen HE, Overø KF. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998;8:147-53. PMID:
9871816
9. Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005;(3):CD005429. PMID:
16034974
10. Asplund R, Johansson S, Henriksson S, Isacsson G. Nocturia, depression and antidepressant medication. BJU Int 2005;95:820-3. PMID:
15794790
11. Movig KL, Leufkens HG, Belitser SV, Lenderink AW, Egberts AC. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002;11:271-9. PMID:
12138594
12. Albayrak S, Solmaz V, Gencden Y, Firat F, Oran Demir M, Aksoy D, et al. Assessment of overactive bladder in women antidepressant users. Int Urol Nephrol 2015;47:1479-84. PMID:
26246036
13. Tarcan T, Mangır N, Özgür MÖ, Akbal C. OAB-V8 Aşırı aktif mesane sorgulama formu validasyon çalışması. Üroloji Bülteni 2012;21:113-6.
14. Cetinel B, Ozkan B, Can G. The validation study of ICIQ-SF Turkish version. Turk J Urol 2004;30:332-8.
15. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71. PMID:
13688369
16. Guay DR. Duloxetine for management of stress urinary incontinence. Am J Geriatr Pharmacother 2005;3:25-38. PMID:
16089245
17. Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther 2012;18:167-74. PMID:
22070184
19. Tonini M, Candura SM. 5-HT4 receptor agonists and bladder disorders. Trends Pharmacol Sci 1996;17:314-6.
20. Bär KJ, Greiner W, Jochum T, Friedrich M, Wagner G, Sauer H. The influence of major depression and its treatment on heart rate variability and pupillary light reflex parameters. J Affect Disord 2004;82:245-52. PMID:
15488253
21. Andersson KE. Treatment of the overactive bladder: possible central nervous system drug targets. Urology 2002;59(5 Suppl 1):18-24. PMID:
12007518
23. Votolato NA, Stern S, Caputo RM. Serotonergic antidepressants and urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:386-8. PMID:
11147747
24. van Kerrebroeck P, Abrams P, Lange R, Slack M, Wyndaele JJ, Yalcin I, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004;111:249-57. PMID:
14961887
25. Viktrup L, Bump RC. Pharmacological agents used for the treatment of stress urinary incontinence in women. Curr Med Res Opin 2003;19:485-90. PMID:
14594520
27. Polimeni G, Salvo F, Cutroneo P, Nati G, Russo A, Giustini ES, et al. Venlafaxine-induced urinary incontinence resolved after switching to sertraline. Clin Neuropharmacol 2005;28:247-8. PMID:
16239768
29. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-58. PMID:
9537821
30. Perry S, McGrother CW, Turner K; Leicestershire MRC Incontinence Study Group. An investigation of the relationship between anxiety and depression and urge incontinence in women: development of a psychological model. Br J Health Psychol 2006;11(Pt 3):463-82. PMID:
16870056
31. Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology 2012;80:90-6. PMID:
22748867
32. Selvaraj J, Kekre AN, Varghese L, Jacob KS. Symptoms, prevalence, and risk factors of overactive bladder in women in south India. Int J Gynaecol Obstet 2015;129:274-5. PMID:
25744339